- To develop directly substitutable, generic mono- and combination therapies for asthma and COPD, utilising where possible existing regulatory guidelines for accelerated approval (e.g. by in vitro equivalence route in Europe).
- To develop ‘super-generic’ (novel) versions of therapies using simple, cost effective already approved devices.
- To develop next generation combination respiratory medicines based on its unique Multi-component Particles™ (MCP™). MCPs™ consist of two or more respiratory drugs combined consistently in a pre-determined ratio in each particle in the formulation. They offer the potential to eliminate the dose variability that comes from the classical physical blending of two drugs in existing combination therapies and to provide co-association and co-localisation of drugs at the target site with the intention of producing an enhanced clinical effect.
Prosonix aims to leverage its technology and expertise to develop its drug development programmes rapidly, and to partner with pharmaceutical companies for primary care sales of novel product candidates.